ArticlePLoS pathogens2026
Long-term depletion of KIR3DL01+ NK cells by adeno-associated viral-vectored antibody delivery alters chronic SIV infection.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Natural killer (NK) cells are key innate effectors during antiviral immune responses, with their activity regulated in part by interactions between polymorphic killer-cell immunoglobulin-like receptors (KIRs) on NK cells and their major histocompatibility complex class I (MHC I) ligands on target cells. In human immunodeficiency virus (HIV) infection, certain KIR and MHC I allelic combinations are associated with enhanced viral control and delayed disease progression. To interrogate the contribution of a common KIR+ NK cell subset to the immune response to simian immunodeficiency virus (SIV) infection of rhesus macaques, we depleted KIR3DL01+ cells using an adeno-associated virus (AAV) vector encoding a KIR3DL01-reactive monoclonal antibody. AAV delivery resulted in high and durable antibody expression with minimal anti-drug antibody responses, leading to sustained depletion of KIR3DL01+ NK cells from blood, lymph nodes, and gut-associated lymphoid tissue for more than nine months. Following intrarectal SIV challenge, there was no difference in peak viremia between the two groups. However, KIR3DL01-depleted animals exhibited a modest increase in chronic viremia, reaching statistical significance at multiple timepoints relative to KIR3DL01+ controls. Phenotypic analysis revealed ongoing NK cell maturation in peripheral blood and lymphoid tissue, accompanied by increased expression of activation and proliferation markers during acute and early chronic infection. An expansion of NKG2D+ NK cells was also observed in chronic SIV infection. These findings suggest that KIR3DL01+ NK cells contribute to the inhibition of SIV replication during chronic infection. Moreover, they demonstrate the feasibility of AAV-vectored antibody delivery for long-term, perhaps indefinite depletion of a lymphocyte subset in a nonhuman primate model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.